한글목차

세계의 동물용 피부과 시장 규모는 2025년 201억 1,000만 달러에서 2030년에는 303억 1,000만 달러에 달할 것으로 예측되며, 예측 기간 중 CAGR은 8.5%에 달할 것으로 보이고 있습니다.

동물용 피부과 시장은 반려동물 인구 증가와 반려동물 사육 증가로 인해 괄목할 만한 성장세를 보이고 있습니다. 인수공통전염병에 대한 우려가 높아지면서 피부과 치료에 대한 수요가 더욱 증가하고 있습니다. 정부와 동물보호단체는 반려동물과 가축의 피부질환을 조기에 진단하고 치료할 수 있도록 장려하고, 인식 개선 활동을 적극적으로 추진하고 있습니다. 또한 반려동물 보험의 보급과 동물 의료비 상승은 전문적인 피부과 치료에 대한 접근성을 향상시켜 시장 성장을 지원하고 있습니다. 그러나 반려동물 의료비 상승이 치료의 보급을 제한하는 등 과제도 있습니다. 또한 기생충 구충제에 대한 내성이 증가하면서 일반적인 피부과 치료의 효과가 감소하고 있는 것도 큰 우려 요인으로 작용하고 있습니다. 이러한 시장 성장 억제요인에도 불구하고 새로운 치료제와 진단 기술을 포함한 동물용 피부과학의 발전은 계속해서 시장 기회를 촉진하고 있습니다.

경구제 부문은 투여가 용이하고 반려동물 보호자의 순응도가 높아짐에 따라 2025-2030년의 예측 기간 중 가장 높은 CAGR로 성장할 것으로 예상됩니다. 정제, 캡슐, 츄어블과 같은 경구용 약품은 외용제나 주사제를 대체할 수 있는 편리한 치료법입니다. 외용제보다 전신 치료를 권장하는 수의사 증가와 선호도가 높은 제형 개발이 수요를 촉진하고 있습니다. 또한 서방형 경구용 제제와 같은 약물전달 시스템의 발전은 동물용 피부과 시장의 성장에 기여하고 있습니다.

동물의 기생충 감염 유병률 증가로 인해 항기생충제 부문은 2024년 가장 큰 시장 점유율을 차지할 것으로 예상됩니다. 벼룩 및 진드기 예방약을 포함한 이러한 약물은 치료와 예방 모두에 널리 사용되고 있습니다. 반려동물 사육 수 증가와 인수공통전염병에 대한 인식이 높아짐에 따라 항기생충 치료제에 대한 수요가 증가하고 있습니다. 또한 여러 기생충을 표적으로 하는 병용요법의 출시는 시장 확대의 원동력이 되고 있습니다. 업계 주요 업체들은 효능을 개선하고 보호 기간을 연장하는 혁신적인 제제를 출시하여 이 부문의 우위를 더욱 강화하고 있습니다.

기생충 감염은 동물용 피부과 시장에서 가장 빠른 성장률을 보일 것으로 예상됩니다. 반려동물의 벼룩, 진드기, 진드기 감염률이 높은 지역, 특히 온난하고 습한 지역에서는 효과적인 치료에 대한 수요가 증가하고 있습니다. 기생충성 피부염은 심한 가려움증, 탈모, 2차 세균 감염을 유발할 수 있으며, 수의사 치료의 필요성이 높아지고 있습니다. 진단 방법의 발전, 처방약 및 일반의약품의 가용성 증가는 이 부문의 빠른 성장에 기여하고 있습니다. 또한 기생충 예방에 대한 보호자들의 인식이 높아지면서 시장 확대가 더욱 가속화되고 있습니다.

반려동물 부문이 2024년 가장 큰 시장 점유율을 차지했는데, 이는 반려동물 사육 증가와 동물 건강관리에 대한 지출 증가에 기인합니다. 개와 고양이는 알레르기, 진균 감염증, 외부 기생충 감염과 같은 피부 질환에 매우 취약하여 잦은 피부과 치료가 필요합니다. 반려동물의 인간화 추세와 고급 수의학에 대한 수요가 증가하면서 시장 성장을 더욱 촉진하고 있습니다. 또한 생물제제 및 표적 치료제를 포함한 피부과 치료제의 발전은 반려동물의 치료 결과를 개선하여 이 부문 시장 지배력을 강화하고 있습니다.

세계의 동물용 피부과 시장에 대해 조사했으며, 투여 경로별, 제품 유형별, 병상별, 동물 유형별, 최종사용자별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 정리하여 전해드립니다.

목차

제1장 서론

제2장 조사 방법

제3장 개요

제4장 주요 인사이트

제5장 시장 개요

• 서론
• 시장 역학
• 업계 동향
• 기술 분석
• Porter's Five Forces 분석
• 규제 상황
• 특허 분석
• 무역 분석
• 가격 분석
• 상환 분석
• 주요 컨퍼런스와 이벤트
• 주요 이해관계자와 구입 기준
• 동물용 피부과 시장에서 미충족 요구/최종사용자 기대
• 동물용 피부과 시장에서 생성형 AI의 영향
• 에코시스템 분석
• 사례 연구 분석
• 공급망 분석
• 밸류체인 분석
• 동물용 피부과 시장의 인접 시장
• 고객 비즈니스에 영향을 미치는 동향/혼란
• 투자와 자금조달 시나리오

제6장 동물용 피부과 시장, 투여 경로별

• 서론
• 국소제
• 주사제
• 경구제

제7장 동물용 피부과 시장, 제품 유형별

• 서론
• 항기생충제
• 항진균제
• 항균제
• 모노클로널 항체
• 기타

제8장 동물용 피부과 시장, 병상별

• 서론
• 기생충 감염증
• 감염증
• 자가면역성 피부 질환
• 피부암
• 기타

제9장 동물용 피부과 시장, 동물 유형별

• 서론
• 반려동물
• 가축

제10장 동물용 피부과 시장, 최종사용자별

• 서론
• 수의 병원 및 진료소
• 동물 보호 시설과 구조
• 기타

제11장 동물용 피부과 시장, 지역별

• 서론
• 북미
  • 거시경제 전망
  • 미국
  • 캐나다
• 유럽
  • 거시경제 전망
  • 독일
  • 영국
  • 프랑스
  • 이탈리아
  • 스위스
  • 스페인
  • 기타
• 아시아태평양
  • 거시경제 전망
  • 일본
  • 중국
  • 인도
  • 호주
  • 뉴질랜드
  • 한국
  • 기타
• 라틴아메리카
  • 거시경제 전망
  • 브라질
  • 멕시코
  • 기타
• 중동 및 아프리카
  • 거시경제 전망
  • GCC 국가
  • 기타

제12장 경쟁 구도

• 개요
• 주요 참여 기업의 전략/강점
• 동물용 피부과 시장에서 주요 기업의 매출 분석(2020-2024년)
• 시장 점유율 분석, 2024년
• 기업 평가 매트릭스 : 주요 참여 기업, 2024년
• 기업 평가 매트릭스 : 스타트업/중소기업, 2024년
• 브랜드/제품 비교
• 주요 기업의 연구개발비
• 기업 가치 평가와 재무 지표
• 경쟁 시나리오

제13장 기업 개요

• 주요 참여 기업
  • ELANCO ANIMAL HEALTH INCORPORATED
  • MERCK & CO., INC
  • VIRBAC
  • ZOETIS INC.
  • BOEHRINGER INGELHEIM INTERNATIONAL GMBH
  • VETOQUINOL
  • DECHRA PHARMACEUTICALS PLC
  • HESTER BIOSCIENCES LIMITED
  • PETIQ, INC.
  • OUROFINO SAUDE ANIMAL
  • SWEDENCARE
  • ORION CORPORATION
  • NORBROOK
  • CEVA SANTE ANIMALE
  • BIMEDA, INC.
• 기타 기업
  • INDIAN IMMUNOLOGICALS LTD.
  • VETANCO
  • CHANELLE PHARMA
  • PEGASUS LABORATORIES, INC.
  • KYORITSU SEIYAKU CORPORATION
  • AVET HEALTH
  • ANIMALDERMA SRLS
  • LETI PHARMA
  • HUVEPHARMA, INC.
  • VETPLUS

제14장 부록

영문목차

The global veterinary dermatology market is projected to reach USD 30.31 billion by 2030 from USD 20.11 billion in 2025, at a CAGR of 8.5% during the forecast period. The Veterinary Dermatology Market is experiencing significant growth, driven by the expanding companion animal population and increasing pet ownership. Growing concerns about infectious zoonotic diseases have further influenced the demand for dermatological treatments. Government and animal welfare organizations are actively promoting awareness initiatives, encouraging early diagnosis and treatment of dermatological conditions in both pets and farm animals. Moreover, the rising adoption of pet insurance and high animal healthcare expenditure are supporting market growth by improving access to specialized dermatological care. However, the market faces challenges such as the rising cost of pet care, which can limit treatment adoption. Additionally, increasing resistance to parasiticides poses a significant concern, reducing the effectiveness of common dermatological treatments. Despite these restraints, advancements in veterinary dermatology, including novel therapeutics and diagnostic techniques, continue to drive market opportunities.

"The Oral segment is projected to grow at the highest CAGR during the forecast period of 2025-2030."

The oral segment is projected to grow at the highest CAGR during 2025-2030 due to its ease of administration and improved pet owner compliance. Oral medications, including tablets, capsules, and chewable formulations, offer a convenient alternative to topical and injectable treatments. Increasing veterinary recommendations for systemic treatments over topical solutions and the development of palatable formulations are boosting demand. Additionally, advancements in drug delivery systems, such as sustained-release oral formulations, contribute to the segment's growth in the veterinary dermatology market.

"Antiparasitic Drugs segment accounted the largest market in 2024 in veterinary dermatology market."

The antiparasitic drugs segment accounted for the largest market share in 2024 due to the rising prevalence of parasitic infections in animals. These drugs, including flea and tick preventives, are widely used for both treatment and prevention. Increasing pet adoption and awareness about zoonotic diseases are fueling the demand for antiparasitic treatments. Moreover, the growing availability of combination therapies that target multiple parasites has driven market expansion. Key industry players are launching innovative formulations with improved efficacy and longer protection durations, further strengthening the segment's dominance.

" Parasitic infection is expected to witness the fastest growth rate in the global veterinary dermatology market."

Parasitic infections are expected to witness the fastest growth rate in the veterinary dermatology market. The high incidence of flea, tick, and mite infestations in pets, especially in warm and humid regions, is driving demand for effective treatments. Parasitic dermatitis can cause severe itching, hair loss, and secondary bacterial infections, increasing the need for veterinary care. Advancements in diagnostic methods and increasing availability of prescription and over-the-counter treatments contribute to the segment's rapid growth. Moreover, heightened pet owner awareness of parasite prevention further supports market expansion.

"Companion animals segment has accounted the largest market share in the veterinary dermatology market."

The companion animals segment accounted for the largest market share in 2024, driven by increasing pet ownership and growing expenditure on animal healthcare. Dogs and cats are highly susceptible to skin conditions such as allergies, fungal infections, and ectoparasitic infestations, necessitating frequent dermatological treatments. The rising trend of pet humanization and demand for premium veterinary care further boost market growth. Additionally, advancements in dermatological therapeutics, including biologics and targeted therapies, enhance treatment outcomes for companion animals, reinforcing the segment's dominance in the market.

"Veterinary Hospitals and Clinics segment is expected to witness the highest growth rate in the global veterinary dermatology market."

Veterinary hospitals and clinics are expected to witness the highest growth rate, driven by the increasing number of veterinary visits and the availability of specialized dermatology services. These facilities provide comprehensive treatment options, including advanced diagnostics, prescription medications, and surgical interventions for severe skin conditions. The rise in dermatology-focused veterinary clinics and expansion of telemedicine services for dermatological consultations contribute to segment growth. Additionally, pet insurance coverage for dermatological treatments encourages pet owners to seek veterinary care, further increasing demand in this segment.

"North America has accounted for the largest market share in 2024."

North America accounted for the largest market share in 2024, supported by a well-established veterinary healthcare infrastructure and high pet ownership rates. The region has a strong presence of leading market players investing in research and development for innovative dermatological treatments. Rising awareness about pet skin health, coupled with increasing spending on veterinary care, drives market expansion. Additionally, the growing demand for premium pet dermatology products, including hypoallergenic shampoos, medicated sprays, and prescription drugs, contributes to North America's market dominance in the global veterinary dermatology industry.

Breakdown of supply-side primary interviews: * By Company Type: Tier 1 - 45%, Tier 2 - 20%, and Tier 3 - 35% * By Designation: C-level - 35%, Director-level - 25%, and Others - 40% * By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Breakdown of demand-side primary interviews: * By Company Type: Vterinary Hospitals and Clinics - 55%, Animal Shelters and Clinics - 30%, and Other End Users - 15% * By Designation: Veterinary Professionals - 35%, Pet Owners - 30%, Livestock Farmers - 25% and Governtment Officers - 10% * By Region: North America - 40%, Europe - 25%, APAC - 20%, Latin America - 10%, Middle East & Africa - 5%

Research Coverage

This report studies veterinary dermatology market based on route of administration, product types, condition types, animal types, end users, and region. The report also studies factors (such as drivers, restraints, opportunities, and challenges) affecting market growth. It analyzes the opportunities and challenges in the market and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micro markets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions and respective countries.

Reasons to Buy the Report

The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one or a combination of the below-mentioned five strategies.

This report provides insights into the following pointers:

• Analysis of key drivers (Expanding companion animal population and pet ownership, Growing concerns about infectious zoonotic diseases, Rising Awareness initiatives by government and animal welfare organizations, Increasing adoption of pet insurance and high animal healthcare expenditure), restraints (Rising pet care costs, Restrictions on use of parasiticides for food-producing animals), opportunities (Technological advancements and product launches, High growth potential in emerging economies, Surging number of veterinary practitioners in developed markets), and challenges (Growing resistance to parasiticides, Diversity in parasite species) influencing the growth of veterinary dermatology market.
• Product Development/Innovation: Detailed insights on upcoming technologies, research and development activities, and product launches in veterinary dermatology market.
• Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various types of veterinary dermatology treatments across regions.
• Market Diversification: Exhaustive information about products, untapped regions, recent developments, and investments in veterinary dermatology market.
• Competitive Assessment: In-depth assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in veterinary dermatology market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
  • 1.2.1 INCLUSIONS AND EXCLUSIONS
• 1.3 STUDY SCOPE
  • 1.3.1 YEARS CONSIDERED
• 1.4 CURRENCY CONSIDERED
• 1.5 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH APPROACH
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key data from secondary sources
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Key data from primary sources
    • 2.1.2.2 Key industry insights
• 2.2 MARKET SIZE ESTIMATION
• 2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
• 2.4 MARKET SHARE ESTIMATION
• 2.5 RESEARCH ASSUMPTIONS
• 2.6 RISK ASSESSMENT
• 2.7 RESEARCH LIMITATIONS
  • 2.7.1 METHODOLOGY-RELATED LIMITATIONS
  • 2.7.2 SCOPE-RELATED LIMITATIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN VETERINARY DERMATOLOGY MARKET
• 4.2 NORTH AMERICA: VETERINARY DERMATOLOGY MARKET OVERVIEW
• 4.3 VETERINARY DERMATOLOGY MARKET: REGIONAL MIX
• 4.4 VETERINARY DERMATOLOGY MARKET, BY COUNTRY
• 4.5 VETERINARY DERMATOLOGY MARKET: EMERGING VS. DEVELOPED MARKETS

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Expanding companion animal population and pet ownership
    • 5.2.1.2 Growing concerns about infectious zoonotic diseases
    • 5.2.1.3 Rising awareness initiatives by government and animal welfare organizations
    • 5.2.1.4 Increasing adoption of pet insurance and high animal healthcare expenditure
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Rising pet care costs
    • 5.2.2.2 Restrictions on use of parasiticides for food-producing animals
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Technological advancements and product launches
    • 5.2.3.2 High growth potential in emerging economies
    • 5.2.3.3 Surging number of veterinary practitioners in developed markets
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Growing resistance to parasiticides
    • 5.2.4.2 Diversity in parasite species
• 5.3 INDUSTRY TRENDS
  • 5.3.1 RISE IN PET OWNERSHIP, HUMANIZATION OF PETS, AND INCREASED FOCUS ON PET WELLNESS PROGRAMS
  • 5.3.2 RISING USE OF DIAGNOSTICS AND WEARABLE TECHNOLOGY FOR EARLY DETECTION
• 5.4 TECHNOLOGY ANALYSIS
  • 5.4.1 KEY TECHNOLOGIES
    • 5.4.1.1 Topical nanomedicine
    • 5.4.1.2 Biologic therapies
  • 5.4.2 COMPLEMENTARY TECHNOLOGIES
    • 5.4.2.1 Phototherapy
    • 5.4.2.2 Hydrotherapy
  • 5.4.3 ADJACENT TECHNOLOGIES
    • 5.4.3.1 Telemedicine platforms
    • 5.4.3.2 Wearable devices
• 5.5 PORTER'S FIVE FORCES ANALYSIS
  • 5.5.1 COMPETITIVE RIVALRY
    • 5.5.1.1 Established players
    • 5.5.1.2 Continuous innovation
  • 5.5.2 BARGAINING POWER OF BUYERS
    • 5.5.2.1 Consolidated veterinary groups
    • 5.5.2.2 Demand for affordable solutions
  • 5.5.3 BARGAINING POWER OF SUPPLIERS
    • 5.5.3.1 Specialized raw materials
    • 5.5.3.2 Quality compliance
  • 5.5.4 THREAT OF SUBSTITUTES
    • 5.5.4.1 Limited alternatives
    • 5.5.4.2 Specialized treatments
  • 5.5.5 THREAT OF NEW ENTRANTS
    • 5.5.5.1 High R&D costs
    • 5.5.5.2 Regulatory requirements
• 5.6 REGULATORY LANDSCAPE
  • 5.6.1 REGULATORY ANALYSIS
  • 5.6.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
• 5.7 PATENT ANALYSIS
  • 5.7.1 PATENT PUBLICATION TRENDS FOR VETERINARY DERMATOLOGY MARKET
  • 5.7.2 INSIGHTS: JURISDICTION AND TOP APPLICANT ANALYSIS
• 5.8 TRADE ANALYSIS
  • 5.8.1 IMPORT AND EXPORT SCENARIO FOR VETERINARY DERMATOLOGY PRODUCTS
• 5.9 PRICING ANALYSIS
  • 5.9.1 AVERAGE SELLING PRICE TREND OF KEY PLAYERS, BY PRODUCT TYPE
  • 5.9.2 AVERAGE SELLING PRICE TREND OF VETERINARY DERMATOLOGY PRODUCT TYPES, BY REGION
• 5.10 REIMBURSEMENT ANALYSIS
• 5.11 KEY CONFERENCES AND EVENTS
• 5.12 KEY STAKEHOLDERS AND BUYING CRITERIA
  • 5.12.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.12.2 BUYING CRITERIA
• 5.13 UNMET NEEDS/END USER EXPECTATIONS IN VETERINARY DERMATOLOGY MARKET
• 5.14 IMPACT OF GENERATIVE AI ON VETERINARY DERMATOLOGY MARKET
• 5.15 ECOSYSTEM ANALYSIS
• 5.16 CASE STUDY ANALYSIS
  • 5.16.1 ZOETIS LAUNCHED APOQUEL TABLET FOR ALLERGIC DERMATITIS
  • 5.16.2 ELANCO LAUNCHED ZENRELIA TABLET FOR CANINE ATOPIC DERMATITIS
  • 5.16.3 VIRBAC LAUNCHED ALLERDERM SPOT-ON TOPICAL PRODUCT FOR SKIN BARRIER REPAIR
• 5.17 SUPPLY CHAIN ANALYSIS
• 5.18 VALUE CHAIN ANALYSIS
• 5.19 ADJACENT MARKETS FOR VETERINARY DERMATOLOGY MARKET
• 5.20 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS
• 5.21 INVESTMENT AND FUNDING SCENARIO

6 VETERINARY DERMATOLOGY MARKET, BY ROUTE OF ADMINISTRATION

• 6.1 INTRODUCTION
• 6.2 TOPICAL
  • 6.2.1 HIGH PREVALENCE OF ECTOPARASITIC INFESTATIONS AMONG PETS TO DRIVE DEMAND
• 6.3 INJECTABLES
  • 6.3.1 RAPID ABSORPTION AND HIGH BIOAVAILABILITY TO FUEL GROWTH OF INJECTABLE PRODUCTS
• 6.4 ORAL
  • 6.4.1 COMPREHENSIVE APPROACH TO MANAGING CHRONIC AND SEVERE DERMATOLOGICAL DISORDERS

7 VETERINARY DERMATOLOGY MARKET, BY PRODUCT TYPE

• 7.1 INTRODUCTION
• 7.2 ANTIPARASITIC DRUGS
  • 7.2.1 HIGH PREVALENCE OF PARASITIC INFECTIONS IN ANIMALS TO DRIVE DEMAND
• 7.3 ANTIFUNGAL DRUGS
  • 7.3.1 INCREASING INSTANCES OF YEAST DERMATITIS AND CANDIDIASIS TO DRIVE DEMAND
• 7.4 ANTIBACTERIAL DRUGS
  • 7.4.1 GROWTH HINDERED BY RISING CONCERNS OVER ANTIMICROBIAL RESISTANCE
• 7.5 MONOCLONAL ANTIBODIES
  • 7.5.1 RISING INVESTMENT IN R&D TO BOOST SEGMENTAL GROWTH
• 7.6 OTHER PRODUCT TYPES

8 VETERINARY DERMATOLOGY MARKET, BY CONDITION TYPE

• 8.1 INTRODUCTION
• 8.2 PARASITIC INFECTIONS
  • 8.2.1 HIGH OCCURRENCE IN BOTH COMPANION AND LIVESTOCK ANIMALS TO DRIVE DEMAND FOR PREVENTIVE MEASURES
• 8.3 INFECTIOUS DISEASES
  • 8.3.1 HIGH PREVALENCE OF FUNGAL INFECTIONS TO DRIVE GROWTH
• 8.4 AUTOIMMUNE SKIN DISEASES
  • 8.4.1 LOWER OCCURRENCE OF THESE DISEASES CONTRIBUTE TO SMALLER MARKET SHARE
• 8.5 SKIN CANCER
  • 8.5.1 GROWING AWARENESS ABOUT IMPORTANCE OF EARLY DETECTION AND TREATMENT OF SKIN CANCER TO DRIVE GROWTH
• 8.6 OTHER CONDITION TYPES

9 VETERINARY DERMATOLOGY MARKET, BY ANIMAL TYPE

• 9.1 INTRODUCTION
• 9.2 COMPANION ANIMALS
  • 9.2.1 DOGS
    • 9.2.1.1 Growing dog population and high pet ownership to drive growth
  • 9.2.2 CATS
    • 9.2.2.1 Growing awareness of feline health to drive growth
  • 9.2.3 HORSES
    • 9.2.3.1 Initiatives related to adoption to drive growth
  • 9.2.4 OTHER COMPANION ANIMALS
• 9.3 LIVESTOCK ANIMALS
  • 9.3.1 CATTLE
    • 9.3.1.1 Economic importance of dairy and beef cattle to drive growth
  • 9.3.2 SWINE
    • 9.3.2.1 Rising global swine population and pork consumption to drive growth
  • 9.3.3 POULTRY
    • 9.3.3.1 Increasing demand for milk and dairy products to drive growth
  • 9.3.4 OTHER LIVESTOCK ANIMALS

10 VETERINARY DERMATOLOGY MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 VETERINARY HOSPITALS AND CLINICS
  • 10.2.1 GROWING DEMAND FOR SPECIALIZED SKINCARE AND TREATMENTS TO DRIVE MARKET
• 10.3 ANIMAL SHELTERS AND RESCUES
  • 10.3.1 NGO AND ANIMAL WELFARE ORGANIZATIONS TO KEEP SUPPORTING DERMATOLOGICAL TREATMENT IN VETERINARY MARKET
• 10.4 OTHER END USERS

11 VETERINARY DERMATOLOGY MARKET, BY REGION

• 11.1 INTRODUCTION
• 11.2 NORTH AMERICA
  • 11.2.1 MACROECONOMIC OUTLOOK
  • 11.2.2 US
    • 11.2.2.1 High pet ownership rates to drive growth
  • 11.2.3 CANADA
    • 11.2.3.1 Rising concerns about pet skin health to drive market
• 11.3 EUROPE
  • 11.3.1 MACROECONOMIC OUTLOOK
  • 11.3.2 GERMANY
    • 11.3.2.1 Rising poultry consumption and dairy industry to drive market
  • 11.3.3 UK
    • 11.3.3.1 Large pet ownership and zoonotic disease prevention to drive market
  • 11.3.4 FRANCE
    • 11.3.4.1 Stable animal healthcare spending to support market growth
  • 11.3.5 ITALY
    • 11.3.5.1 Expanding livestock industry to drive market
  • 11.3.6 SWITZERLAND
    • 11.3.6.1 High standards in animal health to drive growth
  • 11.3.7 SPAIN
    • 11.3.7.1 Growing pet population and strong dairy industry to drive market
  • 11.3.8 REST OF EUROPE
• 11.4 ASIA PACIFIC
  • 11.4.1 MACROECONOMIC OUTLOOK
  • 11.4.2 JAPAN
    • 11.4.2.1 Rising demand for animal products and increasing pet ownership to drive growth
  • 11.4.3 CHINA
    • 11.4.3.1 Expanding urban pet market and high meat consumption to fuel market
  • 11.4.4 INDIA
    • 11.4.4.1 Growing pet adoption and veterinary shortage to drive market
  • 11.4.5 AUSTRALIA
    • 11.4.5.1 Growing pet ownership and rising spending on veterinary care to drive market
  • 11.4.6 NEW ZEALAND
    • 11.4.6.1 Increased pet ownership and demand for advanced dermatology treatments to drive market
  • 11.4.7 SOUTH KOREA
    • 11.4.7.1 Increasing awareness and adoption of preventive healthcare measures to drive market
  • 11.4.8 REST OF ASIA PACIFIC
• 11.5 LATIN AMERICA
  • 11.5.1 MACROECONOMIC OUTLOOK
  • 11.5.2 BRAZIL
    • 11.5.2.1 Strong veterinary infrastructure and expanding livestock industry to drive market
  • 11.5.3 MEXICO
    • 11.5.3.1 Expanding livestock and poultry sectors to drive market
  • 11.5.4 REST OF LATIN AMERICA
• 11.6 MIDDLE EAST & AFRICA
  • 11.6.1 MACROECONOMIC OUTLOOK
  • 11.6.2 GCC COUNTRIES
    • 11.6.2.1 Kingdom of Saudi Arabia (KSA)
      • 11.6.2.1.1 Vision 2030 investments to drive market
    • 11.6.2.2 United Arab Emirates (UAE)
      • 11.6.2.2.1 Significant livestock population to fuel demand
    • 11.6.2.3 Rest of GCC Countries
  • 11.6.3 REST OF MIDDLE EAST & AFRICA

12 COMPETITIVE LANDSCAPE

• 12.1 OVERVIEW
• 12.2 KEY PLAYER STRATEGY/RIGHT TO WIN
• 12.3 REVENUE ANALYSIS OF KEY PLAYERS IN VETERINARY DERMATOLOGY MARKET (2020-2024)
• 12.4 MARKET SHARE ANALYSIS, 2024
  • 12.4.1 RANKING OF KEY MARKET PLAYERS, 2024
• 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 12.5.1 STARS
  • 12.5.2 EMERGING LEADERS
  • 12.5.3 PERVASIVE PLAYERS
  • 12.5.4 PARTICIPANTS
  • 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 12.5.5.1 Company footprint
    • 12.5.5.2 Region footprint
    • 12.5.5.3 Route of administration footprint
    • 12.5.5.4 Product type footprint
    • 12.5.5.5 Condition type footprint
    • 12.5.5.6 Animal type footprint
• 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 12.6.1 PROGRESSIVE COMPANIES
  • 12.6.2 RESPONSIVE COMPANIES
  • 12.6.3 DYNAMIC COMPANIES
  • 12.6.4 STARTING BLOCKS
  • 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024
• 12.7 BRAND/PRODUCT COMPARISON
• 12.8 R&D EXPENDITURE OF KEY PLAYERS
• 12.9 COMPANY VALUATION AND FINANCIAL METRICS
  • 12.9.1 COMPANY VALUATION
  • 12.9.2 FINANCIAL METRICS
• 12.10 COMPETITIVE SCENARIO
  • 12.10.1 PRODUCT APPROVALS/LAUNCHES
  • 12.10.2 DEALS
  • 12.10.3 EXPANSIONS
  • 12.10.4 OTHER DEVELOPMENTS

13 COMPANY PROFILES

• 13.1 KEY PLAYERS
  • 13.1.1 ELANCO ANIMAL HEALTH INCORPORATED
    • 13.1.1.1 Business overview
    • 13.1.1.2 Products offered
    • 13.1.1.3 Recent developments
      • 13.1.1.3.1 Product launches and approvals
      • 13.1.1.3.2 Deals
      • 13.1.1.3.3 Expansions
    • 13.1.1.4 MnM view
      • 13.1.1.4.1 Right to win
      • 13.1.1.4.2 Strategic choices
      • 13.1.1.4.3 Weaknesses and competitive threats
  • 13.1.2 MERCK & CO., INC
    • 13.1.2.1 Business overview
    • 13.1.2.2 Products offered
    • 13.1.2.3 Recent developments
      • 13.1.2.3.1 Product launches and approvals
      • 13.1.2.3.2 Deals
      • 13.1.2.3.3 Expansions
      • 13.1.2.3.4 Other developments
    • 13.1.2.4 MnM view
      • 13.1.2.4.1 Right to win
      • 13.1.2.4.2 Strategic choices
      • 13.1.2.4.3 Weaknesses and competitive threats
  • 13.1.3 VIRBAC
    • 13.1.3.1 Business overview
    • 13.1.3.2 Products offered
    • 13.1.3.3 Recent developments
      • 13.1.3.3.1 Deals
      • 13.1.3.3.2 Expansions
      • 13.1.3.3.3 Other developments
    • 13.1.3.4 MnM view
      • 13.1.3.4.1 Right to win
      • 13.1.3.4.2 Strategic choices
      • 13.1.3.4.3 Weaknesses and competitive threats
  • 13.1.4 ZOETIS INC.
    • 13.1.4.1 Business overview
    • 13.1.4.2 Products offered
    • 13.1.4.3 Recent developments
      • 13.1.4.3.1 Product launches and approvals
      • 13.1.4.3.2 Deals
      • 13.1.4.3.3 Expansions
      • 13.1.4.3.4 Other developments
    • 13.1.4.4 MnM view
      • 13.1.4.4.1 Right to win
      • 13.1.4.4.2 Strategic choices
      • 13.1.4.4.3 Weaknesses and competitive threats
  • 13.1.5 BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    • 13.1.5.1 Business overview
    • 13.1.5.2 Products offered
    • 13.1.5.3 Recent developments
      • 13.1.5.3.1 Product approvals
      • 13.1.5.3.2 Deals
    • 13.1.5.4 MnM view
      • 13.1.5.4.1 Right to win
      • 13.1.5.4.2 Strategic choices
      • 13.1.5.4.3 Weaknesses and competitive threats
  • 13.1.6 VETOQUINOL
    • 13.1.6.1 Business overview
    • 13.1.6.2 Products offered
    • 13.1.6.3 Recent developments
      • 13.1.6.3.1 Product approvals
  • 13.1.7 DECHRA PHARMACEUTICALS PLC
    • 13.1.7.1 Business overview
    • 13.1.7.2 Products offered
    • 13.1.7.3 Recent developments
      • 13.1.7.3.1 Product approvals
      • 13.1.7.3.2 Deals
  • 13.1.8 HESTER BIOSCIENCES LIMITED
    • 13.1.8.1 Business overview
    • 13.1.8.2 Products offered
  • 13.1.9 PETIQ, INC.
    • 13.1.9.1 Business overview
    • 13.1.9.2 Products offered
    • 13.1.9.3 Recent developments
      • 13.1.9.3.1 Other developments
  • 13.1.10 OUROFINO SAUDE ANIMAL
    • 13.1.10.1 Business overview
    • 13.1.10.2 Products offered
  • 13.1.11 SWEDENCARE
    • 13.1.11.1 Business overview
    • 13.1.11.2 Products offered
    • 13.1.11.3 Recent developments
      • 13.1.11.3.1 Deals
  • 13.1.12 ORION CORPORATION
    • 13.1.12.1 Business overview
    • 13.1.12.2 Products offered
  • 13.1.13 NORBROOK
    • 13.1.13.1 Business overview
    • 13.1.13.2 Products offered
    • 13.1.13.3 Recent developments
      • 13.1.13.3.1 Product launches
      • 13.1.13.3.2 Expansions
  • 13.1.14 CEVA SANTE ANIMALE
    • 13.1.14.1 Business overview
    • 13.1.14.2 Products offered
    • 13.1.14.3 Recent developments
      • 13.1.14.3.1 Deals
  • 13.1.15 BIMEDA, INC.
    • 13.1.15.1 Business overview
    • 13.1.15.2 Products offered
    • 13.1.15.3 Recent developments
      • 13.1.15.3.1 Product launches
      • 13.1.15.3.2 Deals
• 13.2 OTHER PLAYERS
  • 13.2.1 INDIAN IMMUNOLOGICALS LTD.
  • 13.2.2 VETANCO
  • 13.2.3 CHANELLE PHARMA
  • 13.2.4 PEGASUS LABORATORIES, INC.
  • 13.2.5 KYORITSU SEIYAKU CORPORATION
  • 13.2.6 AVET HEALTH
  • 13.2.7 ANIMALDERMA SRLS
  • 13.2.8 LETI PHARMA
  • 13.2.9 HUVEPHARMA, INC.
  • 13.2.10 VETPLUS

14 APPENDIX

• 14.1 DISCUSSION GUIDE
• 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 14.3 CUSTOMIZATION OPTIONS
• 14.4 RELATED REPORTS
• 14.5 AUTHOR DETAILS